These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Antibiotic Dosing in Chronic Kidney Disease and End-Stage Renal Disease: A Focus on Contemporary Challenges. Vilay AM Adv Chronic Kidney Dis; 2019 Jan; 26(1):61-71. PubMed ID: 30876619 [TBL] [Abstract][Full Text] [Related]
5. Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate? O'Shea S; Duffull S; Johnson DW Semin Dial; 2009; 22(3):225-30. PubMed ID: 19386073 [TBL] [Abstract][Full Text] [Related]
6. Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View. Eschenauer GA; Lam SW; Mueller BA Semin Dial; 2016 May; 29(3):204-13. PubMed ID: 26756428 [TBL] [Abstract][Full Text] [Related]
7. Vancomycin dosing and monitoring for patients with end-stage renal disease receiving intermittent hemodialysis. Crew P; Heintz SJ; Heintz BH Am J Health Syst Pharm; 2015 Nov; 72(21):1856-64. PubMed ID: 26490819 [TBL] [Abstract][Full Text] [Related]
9. Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring. Croes S; Koop AH; van Gils SA; Neef C Eur J Pharm Sci; 2012 Jan; 45(1-2):90-100. PubMed ID: 22094306 [TBL] [Abstract][Full Text] [Related]
10. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients. Veltri MA; Neu AM; Fivush BA; Parekh RS; Furth SL Paediatr Drugs; 2004; 6(1):45-65. PubMed ID: 14969569 [TBL] [Abstract][Full Text] [Related]
11. Acute Kidney Injury and Renal Recovery with the Use of Aminoglycosides: A Large Retrospective Study. Paquette F; Bernier-Jean A; Brunette V; Ammann H; Lavergne V; Pichette V; Troyanov S; Bouchard J Nephron; 2015; 131(3):153-60. PubMed ID: 26389593 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Heintz BH; Matzke GR; Dager WE Pharmacotherapy; 2009 May; 29(5):562-77. PubMed ID: 19397464 [TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacology of Antibiotics. Eyler RF; Shvets K Clin J Am Soc Nephrol; 2019 Jul; 14(7):1080-1090. PubMed ID: 30862698 [TBL] [Abstract][Full Text] [Related]
14. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
15. [The role of the phenomenon of the redistribution of aminoglycosides in their monitoring and dosage calculation in patients in the terminal stage of kidney failure undergoing systematic hemodialysis treatment]. Siniukhin VN; Darenkov AF; Stetsiuk EA; Nikolaeva NP; Iarmolinskiĭ IS Urol Nefrol (Mosk); 1991; (1):43-7. PubMed ID: 1858206 [TBL] [Abstract][Full Text] [Related]
17. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. Teigen MM; Duffull S; Dang L; Johnson DW J Clin Pharmacol; 2006 Nov; 46(11):1259-67. PubMed ID: 17050791 [TBL] [Abstract][Full Text] [Related]
18. A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. Jang SM; Gharibian KN; Lewis SJ; Fissell WH; Tolwani AJ; Mueller BA J Clin Pharmacol; 2018 Oct; 58(10):1254-1265. PubMed ID: 29746711 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis. Jaffe G; Meyers BR; Hirschman SZ Antimicrob Agents Chemother; 1974 Jun; 5(6):611-6. PubMed ID: 15825414 [TBL] [Abstract][Full Text] [Related]
20. Comparison of antimicrobial dosing recommendations in patients receiving intermittent hemodialysis among drug information resources. Lewis SJ; Bodenhorn D; Na EY; Jang SM J Clin Pharm Ther; 2022 May; 47(5):628-635. PubMed ID: 34866202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]